---
title: Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
date: '2023-10-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37861217/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231021180721&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: Two 12-day courses of teplizumab in children and adolescents
  with newly diagnosed type 1 diabetes showed benefit with respect to the primary
  end point of preservation of β-cell function, but no significant differences between
  the groups were observed with respect to the secondary end points. (Funded by Provention
  Bio and Sanofi; PROTECT ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Two 12-day courses of teplizumab in children and adolescents with newly diagnosed type 1 diabetes showed benefit with respect to the primary end point of preservation of β-cell function, but no significant differences between the groups were observed with respect to the secondary end points. (Funded by Provention Bio and Sanofi; PROTECT ClinicalTrials.gov number, ...